In the first quarter of 2024, the U.S. recorded a spike in drug shortages and among GoodRx's list of the top 20 most common medications, half are in shortage. 

Here are eight new drug shortages to know, according to databases compiled by the FDA and the American Society of Health-System Pharmacists: 

CMS is expected to announce in early 2025 the list of up to 15 Medicare Part D drugs that will be subject to price negotiations in 2025, with negotiated prices expected to be implemented in 2027. 

GLP-1 manufacturers are now offering significant discounts to entice payers and employers to cover their popular medications, The Wall Street Journal reported Sept. 20.

The FDA approved FluMist, a nasal spray flu vaccine for self-administration, making it the first flu vaccine of its kind available for at home use. 

A phase 3 study has shown that tolebrutinib, a drug being tested in treating non-relapsing secondary progressive multiple sclerosis, slowed the progression of disability in patients. 

Drugmakers will discontinue the sales of a controversial class of fentanyl-based painkillers by the end of September, the FDA confirmed Sept. 16. 

Bionpharma is recalling a batch of pneumonia drug Atovaquone Oral Suspension after it was found to be contaminated with Cohnella bacteria. 

Becker's asked chief pharmacy officers from hospitals and health systems across the U.S. to share the next steps in their technological journey.

A pair of recent studies highlighted two potential new uses for metformin, a Type 2 diabetes drug. One points to the drug possibly helping people living with HIV, and another shows the drug could benefit adults who have long COVID-19.